USANA Health Sciences, Inc. — Form 10-Q Summary
Period: Quarter ended September 26, 2020, with nine-month comparisons to September 28, 2019. The request metadata says “2019 Q3,” but the filing itself is for 2020 Q3.
Business context and reporting period
USANA develops and manufactures nutrition, food, and personal-care products sold internationally through independent Associates using a direct-selling network. It reported approximately 650,000 active Customers at September 26, 2020, up 16.5% year over year. Asia Pacific accounted for 80.8% of third-quarter sales; sales outside the United States were 90.6% of nine-month sales.
Financial performance and liquidity
| Metric | Q3 2020 | Q3 2019 | Nine months 2020 | Nine months 2019 |
|---|---|---|---|---|
| Net sales | $298.5 million | $260.6 million | $824.1 million | $789.6 million |
| Gross profit | $242.2 million | $212.8 million | $674.0 million | $649.4 million |
| Gross margin | 81.1% | 81.7% | 81.8% | 82.2% |
| Operating earnings | $45.4 million | $35.5 million | $124.0 million | $101.6 million |
| Net earnings | $30.5 million | $24.2 million | $85.0 million | $69.8 million |
| Diluted EPS | $1.44 | $1.09 | $4.00 | $3.01 |
| Operating cash flow | Not presented for quarter | Not presented for quarter | $112.5 million | $71.0 million |
At September 26, 2020, cash and cash equivalents were $278.4 million, inventories $78.2 million, current assets $386.0 million, and current liabilities $160.9 million. Stockholders’ equity was $389.1 million. No borrowings were outstanding under the revolving credit facility. The facility provides up to $75 million, with possible increases subject to conditions; maturity is August 2025. Covenants require rolling four-quarter adjusted EBITDA of at least $100 million and funded debt to adjusted EBITDA of no more than 2.0:1.
Nine-month investing cash flow was negative $12.5 million, including $13.6 million of property and equipment purchases. Financing cash flow was negative $59.0 million, including $57.0 million of share repurchases. Cash increased by $43.7 million over the period.
Material changes versus comparable periods
- Third-quarter sales rose 14.5% reported and 13.6% excluding currency effects; nine-month sales rose 4.4% reported and 5.9% excluding currency effects.
- Third-quarter net earnings increased 25.9%; diluted EPS increased 32.1%. Nine-month diluted EPS increased 32.9%, supported by higher earnings and a lower diluted share count.
- Quarterly growth was strongest in Southeast Asia Pacific, up 40.5%, and North Asia, up 24.3%. Greater China rose 3.9%. For the nine months, Greater China sales declined 3.1%, while Southeast Asia Pacific rose 18.4% and North Asia 20.5%.
- Active Customers increased 92,000 year over year. Southeast Asia Pacific rose 41.1%; Greater China rose 4.0%.
- Quarterly gross margin fell 60 basis points, while associate incentives increased to 43.9% of sales from 42.6%. SG&A decreased by $0.6 million and was lower as a share of sales, reflecting higher-sales leverage and reduced event and travel spending.
- Nine-month share repurchases totaled $57.0 million, versus $150.0 million in the prior-year period. No shares were repurchased during Q3 2020; $73.0 million remained authorized at quarter-end.
Outlook, commentary, risks, and unusual items
- The filing provides no specific numerical revenue or earnings guidance. Management said it expected to fund operations with operating cash flow and believed available cash, future operating cash flow, and the credit facility were sufficient for foreseeable ordinary-course needs.
- Management said COVID-19 had not materially affected results or caused meaningful supply-chain disruption through the reporting period. Manufacturing facilities remained operational; sales and distribution continued, while in-person events and selling were affected and many activities shifted online. Future effects remained uncertain.
- Management attributed Q3 sales gains partly to global and market-specific incentive programs. It cited market mix and higher relative shipping costs as pressures on gross margin, and lower event and travel costs as benefits to SG&A.
- Key risks include dependence on direct selling and Associates; regulatory and China-related risks; COVID-19 uncertainty; foreign-exchange movements; supply-chain disruptions; and compliance with credit-facility covenants. China-related profit remittances may be delayed under applicable requirements.
- The company completed a $75 million revolving credit facility amendment in August 2020; it reported no outstanding facility debt at quarter-end. Legal matters arise in the ordinary course; management did not believe they would have a material adverse effect, but certain possible contingencies could not be estimated.
- Goodwill and indefinite-lived intangible-asset impairment assessments resulted in no impairment. Management concluded COVID-19 had not triggered additional impairment testing.
Important facts for investors to verify
- Confirm the period: the filing is for Q3 2020, despite the request metadata’s 2019 Q3 label.
- Assess whether customer and sales growth—particularly incentive-driven growth—continues after the quarter, and compare regional trends, including the nine-month decline in Greater China.
- Monitor gross margin, associate incentive costs, inventory levels, and operating cash flow conversion.
- Review the credit agreement’s EBITDA and leverage covenant definitions and headroom; the filing states the thresholds but does not provide covenant headroom here.
- Consider the location and accessibility of cash: $98.1 million was held in China, where remittances may be delayed.
- Evaluate ongoing COVID-19, direct-selling regulatory, currency, supply-chain, and litigation risks, as well as future capital allocation and repurchases.